drug development

Modernizing Antibody Screening Workflows with Live-Cell Analysis

Innovations in monoclonal antibody discovery technologies allow drug developers to capitalize on natural antibody diversity for disease treatment.

Monoclonal antibodies (mAbs) bind to a variety of targets with high affinity and specificity, making them ideal therapeutics. However, traditional approaches to antibody screening workflows are labor intensive, time consuming, and only report snapshots of data. Through live-cell innovations in antibody discovery technologies, drug developers can make the most of the natural diversity in antibodies for treating cancers, chronic inflammation, and infectious diseases. The Incucyte® Live-Cell Analysis System provides real-time data and actionable insights in antibody discovery workflows, including antibody internalization, antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC), and antibody-driven immune cell killing.

Download this white paper from Sartorius to discover

  • How Incucyte® Live-Cell Analysis Systems provide real-time data and actionable insights for routine functional assays in antibody discovery workflows
  • Validated assays that replace traditional end-point techniques, such as FACS or ELISA, for kinetic live-cell analysis during the antibody triage process
  • How Incucyte® reagents and assays streamline workflows for routine studies in 2D and complex 3D cell models

Sponsored by